Non-small cell lung cancer
Conditions
Interventions
Group 1:Chemotherapy combined with immunotherapy
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Lung cancer patients diagnosed with stage IV without brain metastases confirmed by Shanghai Pulmonary Hospital after December 2019; (2) NSCLC confirmed by cytology or histology biopsy; (3) genetic testing showed No sensitive gene mutations EGFR (-), ALK (-), KRAS (-), BRAF (-), ROS1 (-)); (4) Aged 18-70 years old; (5) Estimated survival time is more than 3 months; (6) ECOG (Eastern Cooperative Oncology Group, ECOG) physical fitness score of 0 or 1; (7) hemoglobin in peripheral blood >=100g/L, neutrophil count >= 2.0*10^9/L, platelets The count is >= 100*10^9/L.
Exclusion criteria
Exclusion criteria: (1) Severe or uncontrollable systemic diseases; (2) History of tumors (except early cervical cancer, skin basal cell carcinoma, etc.); (3) Patients with difficulty swallowing or gastrointestinal obstruction; (4) Previous History of gastrointestinal surgery; (5) History of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn's disease, or indeterminate colitis; (6) Persistent, infectious gastroenteritis, colitis or gastritis; persistent or chronic diarrhea of unknown etiology; Clostridium difficile infection (relapse) or Helicobacter pylori infection (untreated); (7) Chronic constipation; (8) Use of the following drugs within the last three months: alkali Bismuth salicylate and other similar bismuth basic salicylate drugs; (9) After evaluation, the researcher believes that the study is not good for patients and is not suitable for other conditions in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR;PR;SD;PD;PFS;OS;Gut microbiome;Fecal metabolomics;Immune factor; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliacation; | — |
Countries
China
Contacts
Public ContactChang Chen
Shanghai Pulmonary Hospital
Outcome results
None listed